Dystonia
Resources for Patients and Caregivers
Cluster Number:
Wiki Number: 14-Dystonia-Medication-Induced
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms: uncontrolled muscle spasms and contractions after antipschotic medicines.
Progression: can become progressively worse
Causes:
Medications:
Therapies: reduce or change medications
Youtube Video: Dystonia-Generalized Dystonia
Amazon or Library Book: Diagnosis Dystonia
Amazon or Library Book:
Living Well with Dystonia
Click the book to link or buy from Amazon.
Click the book to link or buy from Amazon.
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Novel SLC18A2 Variant in Infantile Dystonia-Parkinsonism Type 2by Sakari Kaasalainen on May 8, 2024
Infantile dystonia-parkinsonism type 2 (PKDYS2) is a rare inherited autosomal recessive movement disorder with onset in infancy. The disease is associated with a mutation in the solute carrier family 18 member A2 gene (SLC18A2). There are reports of trials with dopaminergic drugs and the condition of patients given levodopa almost always worsens and dopamine agonists give varying degrees of benefit to some. Here, we report a PKDYS2 patient with a new variant in the SLC18A2 gene who underwent...
- The spectrum of movement disorders in young children with ARX-related epilepsy-dyskinesia syndromeby Shyam K Akula on May 7, 2024
Children with developmental and epileptic encephalopathies often present with co-occurring dyskinesias. Pathogenic variants in ARX cause a pleomorphic syndrome that includes infantile epilepsy with a variety of movement disorders ranging from focal hand dystonia to generalized dystonia with frequent status dystonicus. In this report, we present three patients with severe movement disorders as part of ARX-associated epilepsy-dyskinesia syndrome, including a patient with a novel pathogenic...
- Deep brain stimulation for pediatric pantothenate kinase-associated neurodegeneration with status dystonicus: A case report and literature reviewby Zhenhang Zhai on May 7, 2024
CONCLUSION: This case confirmed the rationality of choosing DBS for the treatment of status dystonicus. Meanwhile, we found that children with classic PKAN have a cluster of risk factors for developing status dystonicus. Once children diagnosed with similar neurodegenerative diseases are under status dystonicus, DBS can be active considered because it has showed high control rate of this emergent condition.
- Deep Brain Stimulation of the Globus Pallidus Internus in a Child with Refractory Dystonia due to L2-Hydroxyglutaric Aciduriaby Abdullah Alamri on May 7, 2024
CONCLUSION: This is the first utilization of DBS as treatment for L2HGA-related dystonia. The resulting significant improvements indicate that pallidal neuromodulation may be a viable option for pharmaco-resistant cases, and possibly in other secondary metabolic dystonias.